罗莫索单抗与特立帕肽在绝经后骨质疏松症女性中的有效性与安全性
基于奥胡斯大学医院内分泌科报销标准纳入315例绝经后女性的观察性研究,比较罗莫索单抗(ROMO)与特立帕肽(TPTD)治疗12个月的效果。ROMO组骨密度(股骨颈、全髋、腰椎)增幅显著大于TPTD组(P<.001),停药率更低,心血管不良事件发生率更低。ROMO完成率及依从性更高。
要点
- ROMO组12个月骨密度增幅显著大于TPTD组:股骨颈4.8% vs 0.2%,全髋5.7% vs 0.3%,腰椎13.7% vs 9.3%(P<.001)。
- ROMO停药率低于TPTD,且心血管不良事件发生率低于TPTD。
- 初治患者骨密度增幅在ROMO和TPTD中均高于经治患者,但差异无统计学显著性。
核心结论
- ROMO治疗12个月后骨密度增幅大于TPTD,完成率更高,依从性更高。
研究设计与样本
- 观察性研究,基于奥胡斯大学医院内分泌科ROMO和TPTD报销标准纳入315例绝经后女性,数据来自病历记录。
主要发现
- 12个月时ROMO组骨密度增幅显著大于TPTD组(P<.001):股骨颈4.8% vs 0.2%,全髋5.7% vs 0.3%,腰椎13.7% vs 9.3%。
- ROMO停药率低于TPTD。
- ROMO心血管不良事件发生率低于TPTD。
- 初治患者骨密度增幅在ROMO和TPTD中均高于经治患者,但差异无统计学显著性。
关键数值与推荐
- ROMO报销标准:骨密度T值<-2.5(股骨颈、全髋或腰椎)且3年内发生脆性骨折(髋、脊柱、骨盆、远端前臂或肱骨近端)。
- TPTD报销标准:3年内≥2处椎体骨折,或1处椎体骨折且骨密度T值(股骨颈、全髋或腰椎)<-3。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this observational study was to investigate the effectiveness and safety of romosozumab (ROMO) and teriparatide (TPTD) in a clinical setting. METHODS: A total of 315 postmenopausal women were included based on the reimbursement criteria for ROMO and TPTD at the Department of Endocrinology at Aarhus University Hospital. Criteria for ROMO were bone mineral density (BMD) T-score < -2.5 (femoral neck [FN], total hip [TH], or lumbar spine [LS]) + a fragility fracture (hip, spine, pelvis, distal forearm, or proximal humerus) within 3 years. Criteria for TPTD: within 3 years, ≥ 2 vertebral fractures or 1 vertebral fracture + BMD T-score (FN, TH, or LS) < -3. Data were collected from medical records. The primary end point was percentage change from baseline in BMD (FN, TH, and LS) at month 12. BMD was measured by dual-energy x-ray absorptiometry (DXA). RESULTS: At month 12, ROMO led to significantly (P < .001) larger increases than TPTD in BMD (FN: 4.8% vs 0.2%, TH: 5.7% vs 0.3%, and LS: 13.7% vs 9.3%). Discontinuation rate was lower with ROMO than with TPTD. Lower incidence of cardiovascular adverse events was observed with ROMO compared to TPTD. Treatment-naïve patients had nonsignificantly higher BMD increases compared to previously treated patients with both ROMO and TPTD. CONCLUSION: Treatment with ROMO yields larger increases in BMD than TPTD after 12 months and a higher rate of completion. ROMO was associated with a higher adherence.
引用
- Hartz MC, Johannessen FB, Harsløf T, et al. The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis. J Clin Endocrinol Metab. 2025. PMID: 39011972. doi:10.1210/clinem/dgae484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。